Skip to main content
. Author manuscript; available in PMC: 2017 May 15.
Published in final edited form as: Exp Cell Res. 2016 Mar 23;344(1):95–102. doi: 10.1016/j.yexcr.2016.03.022

Figure 2.

Figure 2

Real-time PCR revealed that PX-866 and raloxifene altered some levels of hTERT, p21 and SMAD7 following three consecutive days of treatments. (A) Slight reduction of hTERT mRNA was observed following treatment with either 1.0 μM raloxifene alone or 0.4 μM PX-866 alone. Significant reduction was observed when raloxifene was combined with either 0.1 or 0.4 μM PX-866. No transcription reduction was seen when raloxifene was combined with 0.8 μM PX-866. (B) Significantly increased p21 transcript level was observed with raloxifene in combination with 0.8 μM PX-866. (C) A significant decrease in cMYC transcription, an expected target of canonical TGF-β pathway activity, was not exhibited by real-time PCR. No significant change in cMYC mRNA due to raloxifene and/or PX-866 was exhibited. (D) The contribution of raloxifene to the TGF-β pathway was apparent from a slight reduction of SMAD7 transcription to 58% of control following treatment with raloxifene alone. Each value represents mean + SE after three independent repetitions of the experiment. * p < 0.05. ** p < 0.01.